公开(公告)号：US20230173490A1

公开(公告)日：2023-06-08

申请号：US18161450

申请日：2023-01-30

申请人： Orbis Diagnostics Limited

发明人： Matheus Jose Teixeira VARGAS ,  Miriam Cather SIMPSON ,  Mithileshwari CHANDRASEKHAR ,  David Edward WILLIAMS

IPC分类号： B01L3/00 ,  G01N33/543 ,  G01N33/74

CPC分类号： B01L3/502761 ,  B01L3/502715 ,  G01N33/543 ,  G01N33/743 ,  B01L2200/0668 ,  B01L2200/16 ,  B01L2300/0654 ,  B01L2300/0803 ,  B01L2400/0487 ,  B01L2400/06 ,  G01N21/65

摘要： Accordingly, in some embodiments of the disclosure, a multi-chambered assay device is provided, which is configured for arrangement on a disc, as well as configured to process an individual sample. A plurality of such assay devices can be arranged along a periphery of the disc at a distance/radius from the center, such that a plurality of individual samples can be processed, e.g., one per assay device. In addition, in an arrangement that a plurality of assay devices are used, they can be spaced apart such that they balance the disc during rotation (which can be with samples contained in one or more of the assay devices, a plurality, a majority, or all of the assay devices).

公开(公告)号：US11649510B2

公开(公告)日：2023-05-16

申请号：US16956889

申请日：2018-12-26

申请人： Takasago International Corporation

发明人： Azusa Miki ,  Ikuo Terada

IPC分类号： C12Q1/6897 ,  G01N33/50 ,  G01N33/68 ,  G01N33/74 ,  G01N33/497

CPC分类号： C12Q1/6897 ,  G01N33/5008 ,  G01N33/6872 ,  G01N33/74 ,  G01N33/497 ,  G01N2333/705 ,  G01N2333/726 ,  G01N2500/02

摘要： The present invention relates to a screening method for materials that suppress the characteristic body odor of elderly people. The screening method of the present invention is designed such that test substances are screened with olfactory receptors responsive to substances responsible for the characteristic body odor of elderly people to select candidate substances for materials that suppress the characteristic body odor of elderly people, and this method comprises adding a test substance and a substance responsible for the characteristic body odor of elderly people to at least one olfactory receptor polypeptide selected from the group consisting of (a) OR2C1, OR2J2, OR4E2 and OR5P3, and (b) polypeptides which comprise an amino acid sequence sharing an identity of at least 80% with the amino acid sequence of any of the polypeptides in (a) and which are responsive to the substance responsible for the characteristic body odor of elderly people; measuring the response of the olfactory receptor polypeptide to the substance responsible for the characteristic body odor of elderly people; and identifying a test substance that suppresses the response of the olfactory receptor polypeptide on the basis of the measured response. Moreover, the present invention relates to a screening method for trans-2-nonenal odor suppressors and a screening method for trans-2-octenal odor suppressors.

公开(公告)号：US20230127440A1

公开(公告)日：2023-04-27

申请号：US17986255

申请日：2022-11-14

申请人： Sphingotec GmbH

发明人： Andreas BERGMANN ,  Olle MELANDER

IPC分类号： G01N33/68 ,  G01N33/74

摘要： The present invention relates to means and methods suitable for risk prediction of chronic kidney disease (CKD) using Pro-Enkephalin or fragments thereof as biomarker. The risk prediction methods of the invention are intended for healthy subjects and for subjects suffering from diseases such as hypertension, cardiovascular diseases and events, diabetes, metabolic syndrome, obesity, or autoimmune diseases. Subject matter of the invention is also a method of predicting the worsening or improvement of kidney function or dysfunction in healthy and diseased individuals.

公开(公告)号：US20230068436A1

公开(公告)日：2023-03-02

申请号：US17966435

申请日：2022-10-14

申请人： HIROSHIMA UNIVERSITY ,  TERUMO KABUSHIKI KAISHA

发明人： Hisakage FUNABASHI ,  Akio KURODA ,  Hiroya SATO

IPC分类号： G01N33/74 ,  G01N27/02 ,  G01N33/543

摘要： An insulin detection method includes: adding a sample to an electrode having an insulin binding protein immobilized on a surface of the electrode, the insulin binding protein specifically recognizing insulin; and detecting an electrochemical change associated with formation of a complex of the insulin and the insulin binding protein. The insulin binding protein includes: a first region that includes an α-CT segment of an insulin receptor and does not include a β subunit of the insulin receptor, and a second region that includes an L1 domain of the insulin receptor and does not include the β subunit of the insulin receptor; and one of the first region and the second region is immobilized on the surface of the electrode.

公开(公告)号：US20230062697A1

公开(公告)日：2023-03-02

申请号：US17821951

申请日：2022-08-24

申请人： Roche Diagnostics Operations, Inc.

发明人： Dirk Block ,  Roberto Latini ,  Serge Masson ,  Ursula-Henrike Wienhues-Thelen ,  Christian Zaugg ,  Andre Ziegler

IPC分类号： G01N33/68 ,  G01N33/74

摘要： The present invention relates to a method for diagnosing a recent paroxysmal atrial fibrillation. The method is based on the determination of the at least one marker selected from the group consisting of a cardiac Troponin, NT-proBNP (N-terminal prohormone of brain natriuretic peptide), hsCRP, IL-6 (Interleukin-6) and IGFBP7 (Insulin like growth factor binding protein 7) in a sample from the subject, and on the comparison of the, thus, determined amount(s) with a reference amount (reference amounts). Further, the present invention relates to a method for identifying a subject being treatable with anticoagulation therapy. Further envisaged are systems, reagents and kits used in performing the methods disclosed herein.

公开(公告)号：US11524073B2

公开(公告)日：2022-12-13

申请号：US15933406

申请日：2018-03-23

申请人： Meng Zheng ,  Shuguang Lin

发明人： Meng Zheng ,  Shuguang Lin

IPC分类号： C07K16/28 ,  A61K39/395 ,  C07K14/705 ,  G01N33/74 ,  A61P25/36 ,  A61P3/10 ,  A61P37/00 ,  A61P35/00 ,  G01N33/94 ,  A61P15/10 ,  A61P31/12 ,  A61P25/18 ,  G01N33/569 ,  C07K14/725 ,  G01N33/574 ,  G01N33/577 ,  G01N33/68 ,  A61K39/00

摘要： The present invention discloses an application of a β3 adrenergic receptor (ADRB3) as a marker for detecting a plurality of diseases, and an application of anti-human ADRB3 monoclonal antibody in diagnosing a disease and preparing a drug for treating the disease. The present invention finds through research that the ADRB3 is a key receptor in nerve-endocrine-immunoregulatory network, and an ADRB3-mediated signaling pathway regulates proliferation and differentiation of neutrophils, lymphocytes and tumor cells. Under normal circumstances, the ADRB3 maintains the non-specific immunocompetence and specific immunocompetence of an organism, and eliminates pathogenic microorganisms and aged organism tissues to play a role in protecting the organism and anti-aging. Under pathological conditions, excessive activation of the signaling pathway will cause systemic chronic inflammation, and destroy immune homeostasis. Therefore, the ADRB3 can be used as a diagnostic marker and a therapeutic target for a plurality of diseases. Anti-human ADRB3 antibody can specifically bond with the ADRB3, regulate the activity of the ADRB3, has the functions of resisting cancer, inflammation, poisoning, shock, allergy, viral infection, autoimmune disease, disease caused by regenerative dysfunction, autoimmune disease, cachexia, cardiovascular and cerebrovascular disease, neurodegenerative disease and aging, regulating autophagy, treating aging disease, etc., and has important medical value and research and application prospects.

公开(公告)号：US20220390456A1

公开(公告)日：2022-12-08

申请号：US17769826

申请日：2020-10-16

申请人： Board of Regents, The University of Texas System

发明人： Honami NAORA ,  Song Yi KO

IPC分类号： G01N33/574 ,  G01N33/74 ,  C07K16/22 ,  A61K45/06

摘要： Provided herein are methods for predicting whether a cancer patient will respond to treatment with bevacizumab based on determining a level of small extracellular vesicle (sEV)-associated VEGF in the patient. Also provided are methods of treating patients with either bevacizumab or a VEGFR tyrosine kinase inhibitor, a VEGFR neutralizing antibody, or a VEGF ligand trap based on the level of small extracellular vesicle (sEV)-associated VEGF in the patient.

公开(公告)号：US20220372124A1

公开(公告)日：2022-11-24

申请号：US17748405

申请日：2022-05-19

申请人： Eli Lilly and Company

发明人： Catherine Brautigam Beidler ,  Jeffrey Streetman Boyles ,  Daniel Scott Girard ,  Shannon Marie Harlan ,  Michael Parvin Johnson

IPC分类号： C07K16/22 ,  A61P25/04 ,  G01N33/74

摘要： The present invention relates to epiregulin antibodies, compositions comprising the same, and methods of making and/or using the antibodies and/or compositions thereof for chronic pain disorders such as chronic osteoarthritis pain, or chronic diabetic peripheral neuropathy pain, or chronic low back pain.

公开(公告)号：US11474102B2

公开(公告)日：2022-10-18

申请号：US15778222

申请日：2016-11-22

申请人： Massachusetts Institute of Technology

发明人： Michael S. Strano ,  Gili H. Bisker Raviv

IPC分类号： G01N33/543 ,  B82Y15/00 ,  G01N33/53 ,  G01N33/531 ,  G01N33/74

摘要： Corona Phase Molecular Recognition (CoPhMoRe) utilizing a heteropolymer adsorbed onto and templated by a nanoparticle surface to recognize a specific target analyte can be used for macromolecular analytes, including proteins. A variant of a CoPhMoRe screening procedure of single walled carbon nanotubes (SWCNT) can be used against a panel of human blood proteins, revealing a specific corona phase that recognizes fibrinogen and insulin, respectively, with high selectivity.

公开(公告)号：US20220326254A1

公开(公告)日：2022-10-13

申请号：US17584167

申请日：2022-01-25

申请人： UNIVERSITY OF WYOMING ,  University of New Hampshire

发明人： Caleb HILL ,  Jeffrey HALPERN

IPC分类号： G01N33/68 ,  G01N33/543 ,  G01N33/74 ,  B82B3/00

摘要： A biosensor for monitoring surface binding events is disclosed. The biosensor comprises an array of nanoparticles and an analyte responsive polymer. The array of nanoparticles includes a plurality of nanoparticles distributed across the nanoparticle array. The analyte responsive polymer includes a recognition element at a first end of the polymer and a terminus at a second end of the polymer distal from the recognition element, the terminus end being conjugated to the nanoparticles in the array. When the recognition element reacts with an analyte, the analyte responsive polymer creates an electrochemical signal at the surface of the nanoparticle array which can be measured to monitor surface events of the analyte responsive polymer.